Sandbox Reserved 425: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 53: | Line 53: | ||
==Quiz Question 1== | ==Quiz Question 1== | ||
Ponatinib is unique in it's ability to bind to the resistant BCR-ALB because of it's preference to the DFG-out conformation. If a competitive inhibitor was created to prevent Ponatinib from binding to BCR-ALB to further the resistance, what specific | Ponatinib is unique in it's ability to bind to the resistant BCR-ALB because of it's preference to the DFG-out conformation. If a competitive inhibitor was created to prevent Ponatinib from binding to BCR-ALB to further the resistance, what specific structures would the inhibitor need to posses? Consider the unique binding methods of Ponatinib and the DFG-out conformation. | ||
<scene name='48/483882/Active_sitezoom/1'>DFG-out</scene> | |||
a. A small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding. | |||
b. Benzoic acid bonded to another aromatic ring with at least one substituent that creates a large dipole moment; such as a halogen. | |||
b. | |||
c. A polymer chain with an ester linkage and a hydroxyl end group . | |||
d. A metal center that binds four large, nonpolar hydrocarbon ligands that exhibit significant steric hindrance. | |||
==See Also== | ==See Also== | ||
